NYSE:GSK

GSK (GSK) Stock Forecast, Price & News

$37.71

+0.09 (+0.24%)

(As of 11:46 AM ET)

Compare

Today's Range: $37.49
▼
$37.75
50-Day Range: $34.18
▼
$38.07
52-Week Range: $28.47
▼
$39.74

Volume: 1.54 million shs
Average Volume: 3.34 million shs
Market Capitalization: $77.21 billion

P/E Ratio: 4.30
Dividend Yield: 3.74%
Price Target: $37.27

GSK MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 0.9% Downside
$37.27 Price Target
Short Interest: Healthy
0.24% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.26
Based on 18 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 1.86%
From $3.77 to $3.84 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

650th out of 965 stocks

Pharmaceutical Preparations Industry

301st out of 451 stocks

1.0

Analyst's Opinion

Consensus Rating
GSK has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 4 buy ratings, no hold ratings, and 4 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.27, GSK has a forecasted downside of 0.9% from its current price of $37.62.
Amount of Analyst Coverage
GSK has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.24% of the float of GSK has been sold short.
Short Interest Ratio / Days to Cover
GSK has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GSK has recently decreased by 7.79%, indicating that investor sentiment is improving significantly.

3.3

Dividend Strength

Dividend Leadership
GSK is a leading dividend payer. It pays a dividend yield of 3.72%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
GSK does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of GSK is 16.10%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, GSK will have a dividend payout ratio of 36.72% next year. This indicates that GSK will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GSK.

2.4

News and Social Media Coverage

News Sentiment
GSK has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for GSK this week, compared to 7 articles on an average week.
Search Interest
Only 44 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
MarketBeat Follows
28 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GSK insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 10.00% of the stock of GSK is held by insiders.
Percentage Held by Institutions
Only 13.53% of the stock of GSK is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for GSK are expected to grow by 1.86% in the coming year, from $3.77 to $3.84 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GSK is 4.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.97.
Price to Earnings Ratio vs. Sector
The P/E ratio of GSK is 4.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.60.
Price to Earnings Growth Ratio
GSK has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
GSK has a P/B Ratio of 6.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GSK (NYSE:GSK) Stock

GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in Brentford, London. It operates in three main business areas: pharmaceuticals, vaccines and consumer healthcare products. The company has a global presence, operating in over 150 countries and employing over 94,000 people worldwide.

GSK has a long history of innovation and has been responsible for developing some of the world's most important medicines, including treatments for asthma, HIV/AIDS and cancer. The company is also committed to global health initiatives, focusing on improving access to essential medicines in developing countries.

Emma Walmsley has been the CEO of GSK since 2017, becoming the first female CEO of a major pharmaceutical company. She has been instrumental in transforming the company's operations and has led a significant restructuring effort to simplify the business and focus on key growth areas. The management team includes several other key executives, including Dr. Hal Barron, former President of Research and Development, now a Non-Executive Director and Luke Miels, Chief Commercial Officer.

GSK's financial performance has been mixed in recent years. The company's revenue has been relatively flat over the past few years, and rising R&D costs and the impact of COVID-19 on sales have impacted profitability. In Q2 - Q4 of 2022, the company's stock price dropped nearly 40% concerning long-term shareholders. This stock has underperformed the broader market and many of its peers in the pharmaceutical industry. However, this also points to the fact that the stock is undervalued relative to its peers providing good value for would-be investors.

GSK has also undergone significant changes in ownership in recent years. In 2019, the company merged its consumer healthcare business with Pfizer's consumer healthcare business to create a new joint venture. GSK owns a majority stake in the joint venture, which is expected to generate significant cost savings and synergies.

The pharmaceutical industry is highly competitive, with a few major players dominating the market. GSK's primary competitors include Pfizer, Johnson & Johnson and Roche. The industry is also heavily regulated, with stringent drug safety and efficacy requirements.

One of the key trends in the industry is the shift toward personalized medicine, which involves developing treatments tailored to individual patients based on their genetic makeup. GSK has invested heavily in this area, focusing on oncology and rare diseases.

Despite the pharmaceutical industry's challenges, GSK has several growth opportunities in its core business areas. The company has a strong pipeline of new drugs and vaccines in development, including several potential blockbusters. GSK is also expanding its presence in emerging markets, where demand for healthcare products is growing rapidly.

In addition, the company has been exploring opportunities in digital health and artificial intelligence, which could transform how medicines are developed and delivered. GSK is also committed to sustainability and has set ambitious targets to reduce its environmental impact and improve access to healthcare in low-income countries.

The pharmaceutical industry is subject to a range of risks and challenges, including regulatory hurdles, patent expirations and intense competition. GSK is not immune to these risks and faces some specific challenges.

The COVID-19 pandemic is one of the biggest challenges facing GSK. Another risk is the potential for increased regulatory scrutiny. The pharmaceutical industry is pressured to demonstrate that its products are safe and effective. GSK has faced significant fines and penalties for regulatory violations.

GSK faces competition from established players in the industry and new entrants, particularly in digital health. As a result, the company will need to continue to invest in innovation and R&D to maintain its competitive position and drive growth in the future.

GSK Price History

30 days | 90 days | 365 days | Advanced Chart

GSK Stock News Headlines

September 21, 2023 | msn.com

GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia

September 21, 2023 | msn.com

GSK subsidiary ViiV gets EU okay for HIV prevention drug

September 22, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 20, 2023 | reuters.com

European Commission authorises GSK's HIV prevention drug

September 20, 2023 | foxnews.com

European Commission authorizes GSK's HIV prevention drug

September 19, 2023 | msn.com

FDA approves GSK drug Ojjaara for myelofibrosis with anemia

September 18, 2023 | markets.businessinsider.com

Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison

September 17, 2023 | marketwatch.com

GSK Gets FDA OK on Treatment for Myelofibrosis Patients with Anemia

September 22, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

September 17, 2023 | msn.com

CORRECTED-UPDATE 2-US FDA approves GSK's bone marrow cancer therapy

September 17, 2023 | msn.com

GSK Secures FDA Approval for New Blood Cancer Treatment

September 17, 2023 | news.yahoo.com

EU regulator recommends stopping sale of GSK's blood cancer drug

September 15, 2023 | finance.yahoo.com

UPDATE 2-US FDA approves GSK's bone marrow cancer therapy

September 15, 2023 | msn.com

UPDATE 2-EU regulator recommends stopping sale of GSK's blood cancer drug

September 14, 2023 | seekingalpha.com

GSK plc (GSK) Presents at BofA Global Healthcare Conference (Transcript)

September 14, 2023 | uk.finance.yahoo.com

GSK to open £65m drug factory in Hertfordshire

September 13, 2023 | msn.com

Hong Kong will need ‘proper strategy’ for integrating health data for biomedical hub ambitions, pharma giant GSK chair says

September 12, 2023 | msn.com

Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash

September 12, 2023 | forbes.com

How A Pair Of Air Jordans Communicated A Culture Shift

September 12, 2023 | finance.yahoo.com

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

September 7, 2023 | seekingalpha.com

GSK plc (GSK) Citi's 18th Annual BioPharma Conference Transcript

September 4, 2023 | thetimes.co.uk

GSK breathes easy with world-first vaccine for respiratory syncytial virus

September 4, 2023 | msn.com

Japan accepts for review GSK’s Nucala application to treat rhinosinusitis

September 1, 2023 | markets.businessinsider.com

GSK Plc: MHLW In Japan To Review Supplementary New Drug Application For Nucala

September 1, 2023 | marketwatch.com

GSK's Nucala Accepted for Review in Adult Use in Japan

August 31, 2023 | news.yahoo.com

Health officials urge residents to plan immunization shots as new RSV vaccines roll out

August 30, 2023 | finance.yahoo.com

Global Smoking Cessation & Nicotine De-Addiction Product Market 2023-2028: Featuring Players Pfizer, British American Tobacco, JUUL Labs & GSK PLC

See More Headlines

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Ex-Dividend for 7/13 Dividend: 5/18/2023
Dividend Payable: 7/13/2023
Last Earnings: 7/26/2023
Ex-Dividend for 10/12 Dividend: 8/17/2023
Today: 9/22/2023
Dividend Payable: 10/12/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:GSK
CUSIP: N/A
CIK: 1131399
Web: www.gsk.com
Phone: 442080475000
Fax: 44-20-8047-7807
Employees: 69,400
Year Founded: 2000

Price Target and Rating

Average Stock Price Forecast: $37.27
High Stock Price Forecast: $50.43
Low Stock Price Forecast: $24.44
Forecasted Upside/Downside: -0.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $8.76
Trailing P/E Ratio: 4.29
Forward P/E Ratio: 9.98
P/E Growth: 1.98
Net Income: $18.50 billion
Net Margins: 50.26%
Pretax Margin: 20.26%
Return on Equity: 55.93%
Return on Assets: 9.94%

Debt

Debt-to-Equity Ratio: 1.28
Current Ratio: 0.88
Quick Ratio: 0.63

Sales & Book Value

Annual Sales: $36.28 billion
Price / Sales: 2.12
Cash Flow: $4.48 per share
Price / Cash Flow: 8.40
Book Value: $5.79 per share
Price / Book: 6.50

Miscellaneous

Outstanding Shares: 2,047,510,000
Free Float: 1,842,757,000
Market Cap: $77.02 billion
Optionable: Optionable
Beta: 0.68

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Ms. Emma Natasha Walmsley (Age 53)
CEO & Director
Comp: $6.02M

Ms. Julie Belita Brown (Age 61)
CFO & Exec. Director

Ms. Shobie Ramakrishnan
Chief Digital & Technology Officer

Mr. Tony Wood
Chief Scientific Officer

Ms. Sarah Elton-Farr
Head of Investor Relations

Mr. James Ford
Sr. VP & Group Gen. Counsel of Legal & Compliance

Ms. Sally Jackson
Sr. VP of Global Communications & CEO Office

Mr. David Simon Redfern BSc (Hons) (Age 57)
CA, Pres of Corp. Devel.

Ms. Diana Conrad
Chief People Officer

Mr. Philip C. Thomson
Pres of Global Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 4 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.
What is GSK's stock price forecast for 2023?: 8 Wall Street research analysts have issued 12 month price objectives for GSK's shares. Their GSK share price forecasts range from $24.44 to $50.43. On average, they expect the company's share price to reach $37.27 in the next year. This suggests that the stock has a possible downside of 0.9%.
View analysts price targets for GSK or view top-rated stocks among Wall Street analysts.
How have GSK shares performed in 2023?: GSK's stock was trading at $35.14 at the start of the year. Since then, GSK shares have increased by 7.0% and is now trading at $37.6150.
View the best growth stocks for 2023 here.
Are investors shorting GSK?: GSK saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 4,850,000 shares, a decrease of 7.8% from the August 15th total of 5,260,000 shares. Based on an average daily volume of 3,400,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.2% of the company's shares are sold short.
View GSK's Short Interest.
When is GSK's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GSK earnings forecast.
How were GSK's earnings last quarter?: GSK plc (NYSE:GSK) posted its quarterly earnings results on Wednesday, July, 26th. The pharmaceutical company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The pharmaceutical company earned $8.98 billion during the quarter, compared to analyst estimates of $8.49 billion. GSK had a net margin of 50.26% and a trailing twelve-month return on equity of 55.93%.
How often does GSK pay dividends? What is the dividend yield for GSK?: GSK declared a quarterly dividend on Wednesday, July 26th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.3613 per share on Thursday, October 12th. This represents a $1.45 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date of this dividend is Thursday, August 17th.
Read our dividend analysis for GSK.
What ETFs hold GSK's stock?: ETFs with the largest weight of GSK (NYSE:GSK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), Subversive Mental Health ETF (SANE), Sound Equity Dividend Income ETF (DIVY), Sound Equity Income ETF (SDEI), Pacer BioThreat Strategy ETF (VIRS), Horizon Kinetics Medical ETF (MEDX), Altrius Global Dividend ETF (DIVD) and B.A.D. Etf (BAD).

Is GSK a good dividend stock?: GSK (NYSE:GSK) pays an annual dividend of $1.41 per share and currently has a dividend yield of 3.78%. The dividend payout ratio is 16.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 36.72% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.
What guidance has GSK issued on next quarter's earnings?: GSK issued an update on its FY 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $1.99-$2.05 for the period, compared to the consensus EPS estimate of $3.80. The company issued revenue guidance of $39.63 billion-$40.37 billion, compared to the consensus revenue estimate of $37.43 billion.
What other stocks do shareholders of GSK own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).
What is GSK's stock symbol?: GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
Who are GSK's major shareholders?: GSK's stock is owned by a number of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.68%), JTC Employer Solutions Trustee Ltd (0.67%), Royal Bank of Canada (0.38%), State Street Corp (0.35%), Acadian Asset Management LLC (0.21%) and Camber Capital Management LP (0.20%).
View institutional ownership trends.
How do I buy shares of GSK?: Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GSK's stock price today?: One share of GSK stock can currently be purchased for approximately $37.62.
How much money does GSK make?: GSK (NYSE:GSK) has a market capitalization of $77.02 billion and generates $36.28 billion in revenue each year. The pharmaceutical company earns $18.50 billion in net income (profit) each year or $8.76 on an earnings per share basis.
How many employees does GSK have?: The company employs 69,400 workers across the globe.
How can I contact GSK?: GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial